263 related articles for article (PubMed ID: 30892052)
1. Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.
Bull ME; McKernan JL; Styrchak S; Kraft K; Hitti J; Cohn SE; Tapia K; Deng W; Holte S; Mullins JI; Coombs RW; Frenkel LM
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):557-566. PubMed ID: 30892052
[TBL] [Abstract][Full Text] [Related]
2. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus.
Bull ME; Learn GH; McElhone S; Hitti J; Lockhart D; Holte S; Dragavon J; Coombs RW; Mullins JI; Frenkel LM
J Virol; 2009 Jun; 83(12):6020-8. PubMed ID: 19339344
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.
Beck IA; Jang M; McKernan-Mullin J; Bull M; Wagner T; Huang S; Song LY; Nachman S; Krogstad P; Eshleman SH; Wiznia A; Frenkel LM
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):780-8. PubMed ID: 22081867
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
5. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy.
De Pasquale MP; Leigh Brown AJ; Uvin SC; Allega-Ingersoll J; Caliendo AM; Sutton L; Donahue S; D'Aquila RT
J Acquir Immune Defic Syndr; 2003 Sep; 34(1):37-44. PubMed ID: 14501791
[TBL] [Abstract][Full Text] [Related]
6. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
[TBL] [Abstract][Full Text] [Related]
7. Multidrug-resistant HIV viral rebound during early syphilis: a case report.
Giacomelli A; Micheli V; Cattaneo D; Mancon A; Gervasoni C
BMC Infect Dis; 2020 Apr; 20(1):273. PubMed ID: 32264923
[TBL] [Abstract][Full Text] [Related]
8. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.
Usuku S; Noguchi Y; Sakamoto M; Adachi T; Sagara H; Sudo K; Nishizawa M; Kondo M; Tochikubo O; Imai M
Jpn J Infect Dis; 2006 Apr; 59(2):122-5. PubMed ID: 16632914
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
10. Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.
Bull ME; Mitchell C; Soria J; Styrchak S; Williams-Wietzikoski C; Legard J; McKernan-Mullin J; Kraft K; Onchiri F; Stern J; Holte S; Ryan KJ; Acosta EP; La Rosa A; Coombs RW; Ticona E; Frenkel LM
AIDS; 2018 Jul; 32(11):1389-1401. PubMed ID: 29683841
[TBL] [Abstract][Full Text] [Related]
11. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
[TBL] [Abstract][Full Text] [Related]
12. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
Kearney MF; Wiegand A; Shao W; Coffin JM; Mellors JW; Lederman M; Gandhi RT; Keele BF; Li JZ
J Virol; 2016 Feb; 90(3):1369-76. PubMed ID: 26581989
[TBL] [Abstract][Full Text] [Related]
13. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a Novel Humanized Mouse Model To Investigate
Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.
Imamichi H; Crandall KA; Natarajan V; Jiang MK; Dewar RL; Berg S; Gaddam A; Bosche M; Metcalf JA; Davey RT; Lane HC
J Infect Dis; 2001 Jan; 183(1):36-50. PubMed ID: 11106537
[TBL] [Abstract][Full Text] [Related]
16. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.
Frenkel LM; Wang Y; Learn GH; McKernan JL; Ellis GM; Mohan KM; Holte SE; De Vange SM; Pawluk DM; Melvin AJ; Lewis PF; Heath LM; Beck IA; Mahalanabis M; Naugler WE; Tobin NH; Mullins JI
J Virol; 2003 May; 77(10):5721-30. PubMed ID: 12719565
[TBL] [Abstract][Full Text] [Related]
17. HIV-1C proviral DNA for detection of drug resistance mutations.
Huruy K; Mulu A; Liebert UG; Maier M
PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
[TBL] [Abstract][Full Text] [Related]
18. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year.
Bi X; Gatanaga H; Ida S; Tsuchiya K; Matsuoka-Aizawa S; Kimura S; Oka S
J Acquir Immune Defic Syndr; 2003 Sep; 34(1):1-6. PubMed ID: 14501787
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART.
Wang YM; Dyer WB; Workman C; Wang B; Peng NK; Lachireddy K; Chew CB; Sullivan J; Saksena NK
Curr HIV Res; 2007 Mar; 5(2):235-50. PubMed ID: 17346137
[TBL] [Abstract][Full Text] [Related]
20. Genital Shedding of Human Immunodeficiency Virus Type-1 (HIV) When Antiretroviral Therapy Suppresses HIV Replication in the Plasma.
Bull M; Mitchell C; Soria J; Styrchak S; Williams C; Dragavon J; Ryan KJ; Acosta E; Onchiri F; Coombs RW; La Rosa A; Ticona E; Frenkel LM
J Infect Dis; 2020 Aug; 222(5):777-786. PubMed ID: 32274499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
